Brief Article
Copyright ©2013 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Oct 21, 2013; 19(39): 6630-6636
Published online Oct 21, 2013. doi: 10.3748/wjg.v19.i39.6630
Role of ABCG2 expression driven by cisplatin in platinum-containing chemotherapy for gastric cancer
Qiang Zhang, Kun Li, Jian-Hua Xu, Cheng-Gen Zhao, Qi Gao, Bin Wu, Xiao-Yan Liu
Qiang Zhang, Jian-Hua Xu, Cheng-Gen Zhao, Department of Oncology, Shanghai Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200062, China
Kun Li, Linyi Center for Adverse Drug Reaction Monitoring, Linyi 276000, Shandong Province, China
Qi Gao, Department of General Surgery, Shanghai Sixth People’s Hospital, Shanghai Jiaotong University, Shanghai 200233, China
Bin Wu, Xiao-Yan Liu, Department of Pharmacy, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200127, China
Author contributions: Wu B and Liu XY conceived and designed the research; Zhang Q and Xu JH performed the experiments; Zhao CG and Gao Q analyzed the data; Li K provided reagents, materials and analysis tools; Zhang Q wrote the manuscript.
Supported by The Shanghai Municipal Health Bureau, No.20114296; The National Natural Science Foundation of China, No.30901738; Leading Academic Discipline Project of the State Administration of Traditional Chinese Medicine of China
Correspondence to: Xiao-Yan Liu, Professor, Department of Pharmacy, Renji Hospital, School of Medicine, Shanghai Jiaotong University, 1630 Dongfang Road, Pudong New District, Shanghai 200127, China. shdoctor@vip.sina.com
Telephone: +86-21-68383427 Fax: +86-21-68383427
Received: February 2, 2013
Revised: August 31, 2013
Accepted: September 15, 2013
Published online: October 21, 2013
Processing time: 279 Days and 16.5 Hours
Abstract

AIM: To investigate the relationship between increases in expression time of ABCG2 mRNA driven by cisplatin and efficacy of platinum-containing chemotherapy for gastric cancer.

METHODS: Tumor specimens and normal control tissues were collected from 78 patients with gastric cancer treated from January 2008 to December 2011. Fresh tumor tissue obtained from the surgically resected specimens was tested within 6 h. Polymerase chain reaction products were run on 2% agarose gels and analyzed under ultraviolet light after ethidium bromide staining. Increases in ABCG2 mRNA expression time were assessed after cancer cells were incubated with cisplatin, and were divided into terciles and compared in relation to clinical outcomes.

RESULTS: Among groups classified by expression time of ABCG2 mRNA, no significant differences in baseline clinical characteristics and pathological findings were detected. The median overall time was 14.2 (95%CI: 9.7-18.6), 11.4 (95%CI: 6.3-16.5) and 8.1 (95%CI: 5.4-10.8) in patients with low, intermediate and high increases in ABCG2 mRNA expression times (P < 0.05), respectively. Median survival associated with performance status and tumor node metastasis (TNM) stage showed a similar trend, with longer survival and higher risk for mortality associated with lower performance status score and TNM stage. In a multivariate analysis for survival with Cox proportional-hazards model, increased ABCG2 mRNA expression time was an independent predictor for overall survival. Overall survival was longer with increased ABCG2 mRNA expression times ≤ 0.71 than increased ABCG2 mRNA expression times > 0.71, with a hazard ratio for death of 0.855 (95%CI: 0.615-0.962, P = 0.038).

CONCLUSION: Increased ABCG2 mRNA expression time driven by cisplatin is associated with survival of gastric cancer patients, and this may help modify the therapeutic strategies.

Keywords: Gastric cancer; ABCG2 mRNA expression; Cisplatin; Overall survival

Core tip: As a prognostic marker of poor clinical outcome, the high expression of ABCG2 has become a hot research topic and focus. Nevertheless, there are few studies involving the relevance of ABCG2 expression driven by chemotherapeutic agents and its clinical significance. This is the first study examining the impact of increased ABCG2 mRNA expression time driven by cisplatin in vitro in gastric cancer and its relationship with overall survival of the patients.